Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, phase I/II trial to determine the Maximum Tolerated Dose (MTD),
Recommended Phase II Dose (RP2D), and the safety and efficacy of the combination of
nivolumab-ipilimumab plus lurbinectedin in patients with relapsed/recurrent small cell lung
cancer after progression with first-line, platinum-based chemotherapy
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute